Regorafenib (BAY 73-4506) Clinical Trials

4 actively recruiting trials across 1 location

Pipeline

Phase 1: 1Phase 2: 3

Top Sponsors

Zhejiang University1
The Methodist Hospital Research Institute1
Sergey Orlov, MD1
Beijing Friendship Hospital1

Indications

Cancer4
Liver Disease1
Metastatic Colorectal Cancer (CRC)1
Metastatic Colorectal Cancer (mCRC)1
Colorectal Neoplasms1

Other3 trials

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

Phase 2

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Phase 1

Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

Phase 2

Houston, Texas1 trial

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Houston Methodist Neal Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.